Effects of D-003, a Mixture of Very Long Chain Saturated Fatty Acids, and Policosanol on in vivo Lipid Peroxidation in Rats

Abstract

Background:

D-003 and policosanol (CAS 557-61-9), specific and distinct mixtures of high molecular weight primary aliphatic acids and alcohols, respectively, have shown to inhibit lipid peroxidation in vivo, but comparative studies between their effects on lipid peroxidation processes had not been conducted before.

Objective:

To compare the effects of D-003 and policosanol on markers of lipid peroxidation in vivo in rats.

Methods:

Male Wistar rats were distributed into 9 groups: a control group treated with acacia gum/water vehicle, 4 with policosanol and 4 with D-003, both treatments at 5, 25, 100 and 250 mg/kg. Treatments were administered during 4 weeks.

Results:

Both treatments significantly and dose-dependently reduced plasma malondyaldehide (MDA) and total peroxides. Nevertheless, while D-003 was effective from 5 mg/kg, the lowest effective dose of policosanol was 25 mg/kg. The maximal effects of both treatments were obtained with 100 mg/kg, but greater in D-003 than in policosanol group, and the same occurred across all doses tested. MDA concentrations generated with the enzymatic system in liver homogenates were also significantly and dose-dependently inhibited with both treatments. The lowest effective doses of D-003 and policosanol were 5 and 100 mg/kg, respectively, and the highest inhibitions of about 80% (D-003) and 11% (policosanol). D-003 was more effective than policosanol in all comparisons. D-003 was also more effective than policosanol for lowering MDA concentrations generated with the no enzymatic system, but in these conditions policosanol was effective from 25 mg/kg and produced an inhibition somewhat greater (about 29%) than on MDA-generated by the enzymatic system. Both policosanol and D-003 did not modify the activity of endogenous antioxidant enzymes compared with the controls.

Conclusions:

D-003 (5–250 mg/kg) orally administered for 4 weeks was more effective than policosanol for lowering all the lipid peroxidation markers assessed, like plasma MDA and total peroxides, and MDA concentrations generated by the enzymatic and non-enzymatic oxidant systems of liver homogenates. The inhibitions with D-003 were marked and dose-dependent. Neither D-003 nor policosanol modified the activity of enzymes involved in the endogenic antioxidant defensive system.

Key words

Antioxidants - CAS 557-61-9 - D-003, effect on lipid peroxidation, rat - Fatty acids mixture, very long chain - Lipid peroxidation - Policosanol, effect on lipid peroxidation, rat

• References

• 1 World Health Organization: World Health Report 1998: Life in the 21st Century – a vision of all. Geneva (Switzerland): World Health Organization; 1998
• 2 Lipid Research Clinics Program: The Lipid Research Clinics coronary primary prevention trial results II. The relationship of reduction in the incidence of coronary heart disease to cholesterol lowering. JAMA. 1984; 251: 365-374
• 3 Frick MH, Elo O, Happa K, Heinonen OP, Heinsalmi P, Helo P et al. Helsinki Heart Study: primary-prevention with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med. 1987; 317: 1237-1245
• 4 Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4 444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344: 1383-1389
• 5 The Long-Term Intervention with pravastatin in ischaemic disease (LIPID) Study group: Prevention of cardiovascular events and deaths with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998; 339: 1349-1357
• 6 Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 2002; 360: 7-22
• 7 Luscher TF. Biology of the endothelium. Clin Cardiol. 1997; 20 (Suppl 2) II-3-II-10
• 8 Mas R. D-003: A new substance with promising lipid modifying and pleiotropic effects for atherosclerosis management. Drugs of the Future. 2004; 29: 773-786
• 9 Menéndez R, Mas R, Pérez Y, Amor AM, Ledón N, González RM et al. Inhibition of rat lipoprotein lipid peroxidation by the oral administration of D-003, a mixture of very long chain saturated fatty acids. Can J Physiol Pharmacol. 2002; 80: 13-17
• 10 Castaño G, Menéndez R, Mas R, Illnait I, Fernández JC, Pérez Y et al. Effects of D-003 on lipid profile and lipid peroxidation in healthy volunteers. Clin Drug Invest. 2003; 23: 193-203
• 11 Más R. Policosanol. Drugs of the Future. 2000; 25: 569-586
• 12 Fraga V, Menéndez R, Amor AM, Mâs R, González RM, Jimenez S. Effect of policosanol on in vitro and in vivo rat liver microsomal lipid peroxidation. Arch Med Res. 1997; 28: 355-360
• 13 Menéndez R, Fraga V, Amor AM, Mâs R, González RM, Jimenez S. Oral administration of policosanol inhibits in vitro copper ion-induced rat lipoprotein peroxidation. Physiol Beh. 1999; 67: 1-7
• 14 Menéndez R, Mas R, Amor AM, Mâs R, González RM, Jimenez S. Effects of policosanol treatment on the susceptibility of low density lipoprotein (LDL) isolated from healthy volunteers to oxidative modification in vitro. Br J Clin Pharmacol. 2000; 50: 255-262
• 15 Castaño G, Menéndez R, Mas R, Illnait J, Fernández JC, Fernández L et al. Effects of policosanol and lovastatin on lipid profile and lipid peroxidation in patients with dyslipidemia associated with type 2 diabetes mellitus. Int J Clin Pharmacol Res. 2002; 22: 89-99
• 16 Ng CH, Leung KY, Huang Y, Chen ZY. Policosanol has no antioxidant activity in human low-density lipoprotein but increases excretion of bile acids in hamsters. J Agric Food Chem. 2005; 53: 6289-6293
• 17 Menéndez R, Marrero D, Más R, González RM. In vitro and in vivo study of octacosanol metabolism. Arch Med Res. 2005; 36: 113-119
• 18 Gámez R, Mendoza S, Mas R, Mesa R, Castaño G, Rodriguez B et al. Dose-dependent cholesterol-lowering effects of D-003 on normocholesterolemic rabbits. Curr Ther Res Clin Exp. 2000; 61: 8-16
• 19 Castaño G, Mas R, Fernández L, Illnait J, Fernández JC, Mendosa S et al. Effects of D-003 (5–40 mg/day) on lipid profile of patients with Type II hypercholesterolemia: a Phase II clinical study. Clin Drug Invest. 2003; 23: 789-802
• 20 Menéndez R, Más R, Amor AM, González RM, Rodeiros I, Alfonso JL. Inhibition of cholesterol biosynthesis in cultured fibroblasts by D-003, a mixture of very long chain saturated fatty acids. Pharmacol Res. 2001; 44: 299-304
• 21 Menéndez R, Más R, Pérez Y, González RM, Jiménez S. Oral administration of D-003, a mixture of very long chain saturated fatty acids, prevents casein-induced endogenous hypercholesterolemia in rabbits. Can J Physiol Pharmacol. 2003; 82: 22-29
• 22 Menéndez R, Fernández I, Del Rio A, Amor AM, González RM, Fraga V et al. Policosanol inhibits cholesterol biosynthesis and enhances LDL processing in cultured human fibroblasts. Biol Res. 1994; 27: 199-203
• 23 Menéndez R, Arruzazabala ML, Más R, Amor AM, González RM, Carvajal D et al. Cholesterol-lowering effect of policosanol on rabbits with hypercholesterolemia induced by a wheat starch-casein diet. Br J Nutr. 1996; 77: 923-932
• 24 Menéndez R, Amor A, Rodeiro I, Más R, González RM, González CP et al. Policosanol modulates HMGCoA reductase activity in cultured fibroblasts. Arch Med Res. 2001; 32: 8-12
• 25 Singh DK, Li L, Porter TD. Policosanol inhibits cholesterol synthesis in hepatoma cells by activation of AMP-kinases. J Pharmacol Exp Ther. 2006; 106: 107-144
• 26 Mendoza S, Gámez R, Noa M, Más R, Castaño G, Mesa R et al. Comparison of the effects of D-003 and policosanol on lipid profile and endothelial cells in normocholesterolemic rabbits. Curr Ther Res Clin Exp. 2001; 62: 209-220
• 27 Castaño G, Más R, Fernández L, Illaint J, Fernández J, Mendosa S et al. A comparison of the effects of D-003 and policosanol (5 and 10 mg/d) in patients with Type II hypercholesterolemia: a randomized, double-blinded study. Drugs Exp Clin Res. 2005; XXX (Suppl) 31-44
• 28 Jiang ZY, Hunt JV. Wolff SP Detection of lipid hydroperoxides using the FOX method. Anal. Biochem. 1992; 202: 384-389
• 29 Ohkawa N, Ohish Hi, Yagi K. Assay of lipid peroxides in animal tissues by the thiobarbituric acid reaction. Anal Biochem. 1979; 95: 351-358
• 30 Marxwell MA, Haas SM, Beiber LL, Tolbert NE. A modification of the Lowry procedure to simplify protein determination in membrane lipoprotein samples. Anal Biochem. 1987; 87: 206-209
• 31 Lawrence RA, Burk RE. Glutathione peroxydase activity in selenium deficient rat liver. Biochem Biophys Res Comm. 1976; 71: 952-958
• 32 Calberg I, Mannervik B. Purification and characterization of the flavoenzyme gluthathione reductase from rat liver. J Biol Chem. 1975; 250: 5475-5479
• 33 Sazuka Y, Tanizawa H, Takino Y. Effect of adriamycin on the activities of superoxide dismutase, glutathione peroxidase and catalase in tissues of mice. Jpn J Cancer Res. 1989; 80: 89-94
• 34 Gámez R, Rodeiro I, Fernández I, Acosta P. Preliminary evaluation of the cytotoxic and genotoxic potential of D-003: A mixture of very long chain fatty acids. Teratog Carcinog Mutagen. 2002; 22: 175-181
• 35 Menéndez R, Marrero D, Mas R, Fernández I, González L, González RM. In vitro and in vivo study of octacosanol metabolism. Arch Med Res. 2005; 36: 113-119
• 36 Menéndez R, Más R, Pérez Y, González RM, Jiménez J. Cinética de la radiactividad total (RT) tras la administración oral y endovenosa de dosis únicas de 3 H-octacosanoico a ratas. Acta Farm Bonaerense. 2005; 24: 48-60